MPO is a potential biomarker of acute graft-versus-host disease.
作者信息
Ge Bei, Ye Haige
出版信息
Biomark Med. 2013 Jun;7(3):391-3. doi: 10.2217/bmm.13.52.
PMID:23734800
Abstract
摘要
相似文献
1
MPO is a potential biomarker of acute graft-versus-host disease.
Biomark Med. 2013 Jun;7(3):391-3. doi: 10.2217/bmm.13.52.
2
3
Intestinal graft-versus-host-disease staging by video capsule endoscopy.
Endoscopy. 2008 Sep;40 Suppl 2:E144. doi: 10.1055/s-2007-995767. Epub 2008 Jul 16.
4
Mycophenolate mofetil is effective only for involved skin in the treatment for steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Ann Hematol. 2017 Feb;96(2):319-321. doi: 10.1007/s00277-016-2854-0. Epub 2016 Oct 21.
5
Emerging drugs for acute graft-versus-host disease.
Expert Opin Emerg Drugs. 2009 Jun;14(2):219-32. doi: 10.1517/14728210903018891.
6
Biology and management of chronic graft-versus-host disease.
Cancer Treat Res. 2009;144:277-98. doi: 10.1007/978-0-387-78580-6_12.
7
Fecal calprotectin in allogeneic stem cell transplantation for the diagnosis of acute intestinal graft versus host disease.
Bone Marrow Transplant. 2012 Sep;47(9):1241-2. doi: 10.1038/bmt.2011.241. Epub 2012 Feb 6.
8
Interleukin-22 in the diagnosis of active chronic graft-versus-host disease in paediatric patients.
Br J Haematol. 2015 Jan;168(1):142-5. doi: 10.1111/bjh.13068. Epub 2014 Aug 7.
9
Ferritin concentrations correlate to outcome of hematopoietic stem cell transplantation but do not serve as biomarker of graft-versus-host disease.
Ann Hematol. 2013 Aug;92(8):1121-8. doi: 10.1007/s00277-013-1737-x. Epub 2013 Apr 19.
10
Transplantation with peripheral blood stem cells from unrelated donors without serious graft-versus-host disease.
Bone Marrow Transplant. 1995 Dec;16(6):856-7.
Zotero 插件